Microscopy of tuberculous epididymitis, for article on streptomycin isolation

Albert Schatz isolates streptomycin, the first antibiotic cure for tuberculosis

On October 19, 1943 C.E., a 23-year-old PhD student working in a basement laboratory at Rutgers University pulled a sample from a soil culture and changed the course of medicine. Albert Schatz had just isolated streptomycin — the first antibiotic capable of killing the bacterium behind tuberculosis, a disease that had claimed more human lives than almost any other in recorded history.

Key findings

  • Streptomycin isolation: Schatz extracted the compound from Streptomyces griseus, a soil-dwelling microorganism, in October 1943 C.E. — the first antibiotic shown to be active against tuberculosis.
  • Tuberculosis treatment: Before streptomycin, TB had no reliable cure; it killed roughly one in seven people in industrialized nations throughout the 19th and early 20th centuries C.E.
  • Randomized clinical trial: The first randomized trial of streptomycin against pulmonary TB, conducted from 1946 to 1948 C.E. by the U.K.’s Medical Research Council, is now widely recognized as one of the first randomized curative trials in the history of medicine.

A cure born in the soil

Tuberculosis is ancient. Evidence of the disease appears in Egyptian mummies and in bones from Neolithic Europe. For millennia, it killed quietly and steadily — in the lungs, the spine, the lymph nodes — and medicine had almost nothing to offer in return.

That changed when scientists began looking seriously at soil microbes. Selman Waksman, Schatz’s doctoral supervisor at Rutgers University, had spent decades studying actinomycetes — a group of bacteria found in soil that naturally produce compounds lethal to other microbes. His lab had already identified several such compounds, though none effective against TB. Schatz, working with urgency and little funding, screened hundreds of cultures before isolating Streptomyces griseus and extracting streptomycin from it.

The Rutgers team published their findings in January 1944 C.E. Within months, they were collaborating with researchers at the Mayo Clinic to begin animal trials. A study using just 10 grams of the scarce drug in guinea pigs demonstrated survival — enough to convince Merck & Co. to redirect resources toward commercial production.

How streptomycin works

Streptomycin belongs to a class of antibiotics called aminoglycosides. It works by binding irreversibly to the 30S ribosomal subunit of bacterial cells — essentially jamming the machinery bacteria use to manufacture proteins. Without functioning protein synthesis, the cell cannot survive.

At low concentrations, streptomycin targets bacterial ribosomes without fatally disrupting human cells, though the margin is narrow enough that side effects — particularly hearing loss and kidney toxicity — are real risks. Those risks were accepted, in the 1940s C.E., as vastly preferable to TB’s near-certain death sentence.

The World Health Organization now lists streptomycin as an essential medicine and classifies it as critically important for human medicine — recognition that its core function remains relevant even in an era of far newer drugs.

Lasting impact

The isolation of streptomycin did more than cure TB. It proved that antibiotics were not a one-off phenomenon — that the natural world contained a vast pharmacopeia waiting to be found in soil, in fungi, in the microbial communities beneath our feet. The search for new antibiotics intensified, and the discipline of soil microbiology gained new urgency and prestige.

The Medical Research Council’s streptomycin trial of 1946–1948 C.E. also left a methodological legacy as significant as the drug itself. Its use of random allocation to treatment and control groups helped establish the randomized controlled trial as the gold standard of medical evidence — a framework that now underlies virtually all clinical medicine.

Robert Dole, who later served as U.S. Senate Majority Leader and ran for president, was the third patient treated with streptomycin at a military hospital in Battle Creek, Michigan, in March 1946 C.E. He experienced what the historical record describes as a rapid and robust recovery — a detail that grounds this milestone in individual human lives, not just statistics.

TB mortality fell dramatically in the decades that followed. The U.S. Centers for Disease Control and Prevention tracks ongoing progress in TB elimination, a goal that streptomycin made conceivable for the first time in human history.

Blindspots and limits

The Nobel Prize in Physiology or Medicine was awarded in 1952 C.E. to Selman Waksman alone — a decision that erased Schatz’s name from history for decades. Schatz sued for recognition and a share of the royalties; he eventually received 3% and back compensation, but the Nobel committee never revisited the award. Elizabeth Bugie, who contributed meaningfully to the lab’s work on antimicrobials and co-authored the original paper, was not listed on the patent and received a 0.2% royalty share — a reminder that scientific credit has rarely been distributed equitably, particularly for women researchers.

Streptomycin also came with a problem built into its success: bacterial resistance. Early clinical trials showed that Mycobacterium tuberculosis could develop resistance to the drug, particularly when it was used alone. That finding drove the development of combination therapy — using multiple drugs simultaneously — which remains the cornerstone of TB treatment today. TB still kills more than a million people each year globally, and drug-resistant strains pose a serious ongoing threat.

Read more

For more on this story, see: Wikipedia — Streptomycin

For more from Good News for Humankind, see:

About this article

  • 🤖 This article is AI-generated, based on a framework created by Peter Schulte.
  • 🌍 It aims to be inspirational but clear-eyed, accurate, and evidence-based, and grounded in care for the Earth, peace and belonging for all, and human evolution.
  • 💬 Leave your notes and suggestions in the comments below — I will do my best to review and implement where appropriate.
  • ✉️ One verified piece of good news, one insight from Antihero Project, every weekday morning. Subscribe free.

More Good News

  • Rows of solar panels in a Chinese desert reflecting China wind and solar capacity growth under the Five-Year Plan clean energy targets

    China plans to double its already massive clean energy supply by 2035

    China’s new climate pledge to the United Nations sets a target of 3,600 gigawatts of wind and solar power by 2035 — more than the entire electricity-generating capacity of the United States today, and roughly double what China has already built. The commitment is woven into the country’s next Five-Year Plan, which directs state banks, provinces, and manufacturers to move in the same direction. Because China makes about 80% of the world’s solar panels, every factory it scales up makes clean energy cheaper for buyers in Africa, Southeast Asia, Latin America, and everywhere else. That ripple effect is what makes…


  • Medical researcher in a lab examining vials related to asthma and COPD treatment and mRNA vaccine development, for article on benralizumab injection

    Doctors hail first breakthrough in asthma and COPD treatment in 50 years

    Benralizumab, a single injection given during an asthma or COPD attack, outperformed the steroid pills that have been the only emergency option since the 1970s. In a King’s College London trial of 158 patients, those who got the shot had four times fewer treatment failures over 90 days, along with easier breathing and fewer follow-up visits. Because steroids carry real risks with repeated use — diabetes, osteoporosis, and more — a genuine alternative could change daily life for millions of people who live in fear of the next flare-up. After a half-century of stalled progress on diseases that claim 3.8…


  • A nurse in a rural Mexican clinic checks a patient's blood pressure, for an article about Mexico universal healthcare

    Mexico launches universal healthcare for all 133 million citizens

    Mexico universal healthcare is now officially a reality, with the country launching a system designed to cover all 133 million citizens through the restructured IMSS-Bienestar network. Before this reform, an estimated 50 million Mexicans had no formal health insurance, with rural and Indigenous communities bearing the heaviest burden of untreated illness and medical debt. The new system severs the long-standing tie between employment and healthcare access, providing free consultations, medicines, and hospital services regardless of income. If implemented effectively, Mexico’s move could serve as a powerful model for other middle-income nations still navigating fragmented, inequitable health systems.



Coach, writer, and recovering hustle hero. I help purpose-driven humans do good in the world in dark times - without the burnout.